Abbott has returned for the first close of insulin technology developer Bigfoot Biomedical’s series C round, after backing its $55m series B two years ago.
Medical device manufacturer Abbott led the $45m first tranche of a series C round for US-based diabetes management platform Bigfoot Biomedical on Monday.
Quadrant Capital Advisors, Senvest Capital, Janus Henderson and Cormorant Asset Management also contributed capital to the close.
Bigfoot is working on a system that uses machine learning to automate insulin injections for patients living with diabetes. Data collected by insulin pumps and injection pens is aggregated in a mobile app that can be used by the patient…
Thierry Heles
Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
